Picture of Immunovant logo

IMVT — Immunovant News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapNeutral

Immunovant Inc reports results for the quarter ended in June - Earnings Summary

* Immunovant Inc  IMVT.OQ  reported a quarterly adjusted
loss
of 35 cents​​ per share for the quarter ended in June. The mean
expectation of eight analysts for the quarter was for a loss
of 40 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Immunovant Inc's reported EPS for the quarter was a loss
of 35
cents​.
    * The mean earnings estimate of analysts had risen by
about 4.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Immunovant Inc shares had risen by 22.1% this quarter and
lost 44.1% so far this year.
    * The company reported a quarterly loss of $40.37 million.
    * Wall Street's median 12-month price target for Immunovant
Inc is
$12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 8
at 12:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.40          -0.35          Beat
 Mar. 31 2022      -0.38          -0.41          Missed
 Dec. 31 2021      -0.33          -0.36          Missed
 Sep. 30 2021      -0.28          -0.35          Missed

Recent news on Immunovant

See all news